Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for.
S Strong 1,2, NS Blencowe 1,2,T Fox 1, C Reid 3, T Crosby 4, H.Ford 5, J M Blazeby 1,2 1 School of Social and Community Medicine, Canynge Hall, University.
LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.
Relapse in Diffuse Large B-cell Lymphoma Treatments
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD
LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy • Clinical studies • Meta-analysis
The role of multi-disciplinary teams in decision
